Because CD4 T effector cells with tumor-killing capacity are known to preferentially lyse targets via the Fas/Fas ligand (FasL) interaction60, we tested whether the Fas/FasL axis is involved in converted Treg cell-mediated tumor killing by blocking the Fas receptor with an anti-Fas antibody. This evidence concerns the gene CD4 and neoplasm.